All articles tagged: Opioid abuse, uncomplicated (F11.10)
HealthDay
12 July at 03.43 PM
More Than Half Do Not Know Primary Care Providers Can Treat Opioid Use DisorderMany people do not know that a primary care provider (PCP) can provide medication for opioid use disorder (MOUD), according to a research letter published online June 28 in JAMA Network Open.Brandon del Pozo, Ph.D., from the Brown University School of Public Health in Providence, Rhode Island, and colleagues surveyed 1,234 individu |
HealthDay
08 July at 09.36 PM
Acupuncture Can Reduce Methadone Dose, Opioid CravingFor individuals with opioid use disorder receiving methadone maintenance treatment (MMT), eight weeks of acupuncture is superior to sham acupuncture for reducing methadone dose and opioid craving, according to a study published online July 9 in the Annals of Internal Medicine.Liming Lu, M.D., from the Guangzhou University of Chinese Medi |
HealthDay
25 June at 03.04 PM
ADHD Meds May Help Control Opioid Use Disorder in PregnancyPsychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental Health.Kevin Y. Xu, M.D., M.P.H., from the Washington University School of Medicine in St. Louis, and colleagues used U.S. multistate administrative data to examine the risks and benef |
HealthDay
20 June at 03.52 PM
About One-Third of Mental Health Facilities Offer Meds for Opioid AddictionAbout one-third of community outpatient mental health treatment facilities (MHTFs) offer medications for opioid use disorder (MOUD), according to a study published online June 18 in JAMA Network Open.Jonathan Cantor, Ph.D., from RAND in Santa Monica, California, and colleagues quantified the availability of MOUD at community outpatien |
HealthDay
17 June at 04.09 PM
Few Receive Meds for Opioid Use Disorder After Nonfatal OverdoseIn the 12 months after a nonfatal overdose, few Medicare beneficiaries receive medications for opioid use disorder (MOUD) or fill a naloxone prescription, according to a study published online June 17 in JAMA Internal Medicine.Christopher M. Jones, Pharm.D., Dr.P.H., from the Substance Abuse and Mental Health Services Administration in |
HealthDay
25 January at 03.14 PM
FDA Issues Another Warning on Tianeptine Products, Which Can Cause Seizures and DeathReiterating a warning first issued in November, the U.S. Food and Drug Administration is urging Americans to stay away from supplements containing tianeptine, known on the street as "gas station heroin."The supplements, sold under the brand name Neptune's Fix online and at gas stations and convenience stores, can cause seizures, unconsciousnes |
HealthDay
20 January at 12.01 AM
Study IDs Risks to Offspring Associated With Prenatal Opioid ExposurePrenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan. 17 in JAMA Network Open.Erin Kelty, Ph.D., from the University of Western Australia in Crawley, and colleagues com |
HealthDay
17 January at 11.52 PM
New Rx for Schedule-II Stimulants for ADHD Increased During PandemicIncident use of common behavioral health medications remained relatively stable during the COVID-19 pandemic, with the exception of those for attention-deficit/hyperactivity disorder (ADHD), according to a study published online Jan. 10 in JAMA Psychiatry.Grace Chai, Pharm.D., M.P.H., from the U.S. Food and Drug Administration i |
HealthDay
09 January at 05.00 PM
Access to Residential Addiction Treatment Centers for Teens LimitedFor adolescents, access to U.S. residential addiction treatment centers is limited and costly, according to a study published in the January issue of Health Affairs.Caroline A. King, M.P.H., from Oregon Health & Science University in Portland, and colleagues identified 160 residential addiction treatment facilities that treated adol |
HealthDay
08 January at 04.56 PM
Mindfulness-Oriented Recovery Enhancement Boosts Methadone TreatmentTelehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P |
HealthDay
08 January at 04.56 PM
Mindfulness-Oriented Recovery Enhancement Boosts Methadone TreatmentTelehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P |
Evalytics
22 December at 02.27 PM
Could a little-known psychedelic drug treat opioid addiction? Kentucky wants to find out.Kentucky is seeking federal approval to study ibogaine, a psychedelic drug from West Africa, as a potential treatment for opioid addiction. Ibogaine has shown promise in reducing withdrawal symptoms and cravings, presenting an alternative approach to traditional addiction treatments. |
HealthDay
21 December at 11.17 PM
FDA Approves DNA Cheek Swab Test to ID Patients at High Risk for Opioid AddictionThe U.S. Food and Drug Administration has approved a first-of-its-kind test -- the AvertD test -- that uses DNA swabbed from a patient's cheek to determine if they have a combination of genetic variants associated with an elevated risk for opioid addiction.The 15 genetic variants detected by the test are involved in the brain reward pathways t |
Evalytics
18 December at 05.42 PM
Could a little-known psychedelic drug treat opioid addiction? Kentucky wants to find out.Kentucky is launching a pilot program to study the use of the psychedelic drug ibogaine as a potential treatment for opioid addiction, despite its federal illegality. Derived from a West African shrub, ibogaine shows promise in combating the opioid crisis, and this initiative seeks to assess its effectiveness and safety. |
HealthDay
15 November at 11.02 PM
Opioid Rx Down, but Overdoses and Deaths Up, AMA Report ShowsOpioid prescribing by physicians and other health professionals has decreased for the 13th consecutive year, down nearly 50 percent since 2012, while overdoses and deaths related to illicitly manufactured fentanyl, xylazine, and other synthetic substances continue to increase, according to the Overdose Epidemic Report 2023, released by |
Evalytics
31 October at 04.46 PM
Telemedicine for Buprenorphine Initiation: Revolutionizing Opioid Use Disorder TreatmentIn recent years, the healthcare industry has witnessed a transformative shift towards telemedicine. This innovative approach to healthcare delivery has proven to be not only convenient but also highly effective, especially in addressing complex issues like opioid use disorder. In this article, we will explore how telemedicine has revolutionized the initiation of buprenorphine treatment for individ |
MedScape
28 November at 01.50 AM
Sleep-Disordered Breathing Common After StrokeSleep-disordered breathing remains common after stroke, affecting 60% of patients and showing no decline in prevalence from 2010 to 2023, a new meta-analysis suggested. |
Medpage Today
24 November at 08.00 PM
IDH Inhibitor Activity in Brain Cancer Persists With Longer Follow-UpHOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow-up analysis of a pivotal clinical... |
Medical xPress
23 November at 01.50 PM
RNA editing is the next frontier in gene therapy—here's what you need to knowThe United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide. |
HealthDay
22 November at 04.44 PM
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use DisorderSemaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA Psychiatry.Markku Lähteenvuo, M.D., Ph.D., from the University of Eastern Finland in Kuopio, and colleagues conducted an observational study in Sweden using data from |
Medpage Today
17 November at 10.31 PM
Two Treatments That Don't Work for OsteoarthritisWASHINGTON -- If you're looking for nonsurgical osteoarthritis (OA) treatments with fewer side effects than ordinary pain relievers, two randomized trials presented here with negative results should at least narrow your search... |
MedScape
11 November at 07.56 AM
Scoring System Could Mean Better Access to Lung TransplantScoring system could improve access for hard-to-match candidates due to height and blood type. |
Medical xPress
07 November at 07.50 AM
How key results could influence health policyThe results of some congressional races may foreshadow who will have outsize health policy influence in Congress next year. |
Medpage Today
05 November at 07.00 PM
Mpox Cases in Congo May Be StabilizingGOMA, Congo -- Some health officials say mpox cases in Congo appear to be "stabilizing" -- a possible sign that the main epidemic for which the World Health Organization (WHO) made a global emergency declaration in August... |
Medical xPress
02 November at 07.40 AM
Insulin resistance caused by sympathetic nervous system over-activation, a paradigm-shifting study findsRutgers Robert Wood Johnson Medical School and collaborating institutions have found that overnutrition leads to insulin resistance and metabolic disorders through increased activity of the sympathetic nervous system (SNS). The study shows that reducing SNS activity can prevent insulin resistance induced by a high-fat diet, suggesting a new understanding of how obesity causes insulin resistance. |
MedScape
31 October at 06.30 AM
Report: Rethink Race-Based Adjustments in Clinical ToolsThe slow adoption of race-neutral tools may harm patient care outcomes, according to a new report from the National Academies of Sciences, Engineering, and Medicine. |